Guideline of guidelines: follow-up after orchidectomy for clinical stage 1 testicular cancer.
guideline
non-seminomatous germ cell tumours
outcomes
schedules
seminoma
surveillance
testicular cancer
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
pubmed:
6
7
2023
medline:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Several medical organisations have developed evidence-based guidelines for the diagnosis, management, and follow-up of testicular cancer. This article aimed to review, compare, and summarise the most updated international guidelines and surveillance protocols for clinical stage 1 (CS1) testicular cancer. We reviewed a total of 46 articles on proposed follow-up strategies for testicular cancer, and six clinical practice guidelines including four guidelines published by urological scientific associations and two guidelines published by medical oncology associations. Most of these guidelines have been developed by panels of experts with different backgrounds in clinical training, and geographic practise patterns, which explains the considerable variability between published schedules, and recommended follow-up intensity. We present you with a comprehensive review of the most important clinical practice guidelines and propose unifying recommendations based on the most up to date evidence to help standardise follow-up schedules based on patterns and risk of disease relapse.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
485-495Informations de copyright
© 2023 BJU International.
Références
UK CR: Testicular cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/testicular-cancer. Accessed September 20, 2022
Nason GJ, Chung P, Warde P et al. Controversies in the management of clinical stage 1 testis cancer. Can Urol Assoc J 2020; 14: E537-E542
Nason GJ, Leao R, Hamilton RJ. Active surveillance in stage 1 disease: standard of care independent of risk factors? Curr Opin Urol 2020; 30: 245-250
Chung P, Daugaard G, Tyldesley S et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med-us 2015; 4: 155-160
Goldberg H, Klaassen Z, Chandrasekar T, Fleshner N, Hamilton RJ, Jewett MAS. Germ cell testicular tumors - contemporary diagnosis, staging and management of localized and advanced disease. Urology 2018; 125: 8-19
Sturgeon JF, Jewett MA, Alison RE et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol Official J Am Soc Clin Oncol 1992; 10: 564-568
Dieckmann K-P, Dralle-Filiz I, Heinzelbecker J et al. Seminoma clinical stage 1 - patterns of care in Germany. Urol Int 2016; 96: 390-398
Bobrowski A, Anson-Cartwright L, Kuhathaas K et al. Role of lactate dehydrogenase (LDH) in identifying relapse for patients with stage I testicular cancer on surveillance. J Urol 2022; 208: 1258
Hamilton RJ, Nayan M, Anson-Cartwright L et al. Treatment of relapse of clinical stage I nonseminomatous germ cell tumors on surveillance. J Clin Oncol 2019; 37: 1919-1926
Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008; 19: 443-447
Lu K. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 2015; 33: 2322
Hamilton RJ, Jewett MAS, Warde P, Hansen A. Optimal management of high-risk stage I nonseminomatous germ cell tumor: surveillance is the preferred option. Eur Urol Focus 2019; 5: 702-703
Sturgeon JF, Moore MJ, Kakiashvili DM et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the princess margaret hospital's experience. Eur Urol 2011; 59: 556-562
Laguna MP, Albers P, Algaba F et al. EAU testicular cancer guidelines. Edn. Presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5. 2022
Hamilton RJ, Canil C, Shrem NS et al. Canadian urological association consensus guideline: management of testicular germ cell cancer. Can Urol Assoc J 2022; 16: 155-173
Catton C, Hamilton R. Princess Margaret Cancer Centre Clinical Practice Guidelines Genitourinary Testis Cancer. 2016: 1-26
Lieng H, Warde P, Bedard P et al. Recommendations for followup of stage I and II seminoma: the princess margaret cancer Centre approach. Can Urol Assoc J 2017; 12: 59-66. Accessed November 7, 2022
T G: National Comprehensive Cancer Network. Testicular Cancer (Version 2.2022). 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. Accessed September 10, 2022
Oldenburg J, Berney DM, Bokemeyer C et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 362-375
Stephenson A, Eggener SE, Bass EB et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urology 2019; 202: 272-281
ANZUP GCS of: Stage 1 Testicular Cancer Surveillance Recommendations. Available at: https://anzup.org.au/wp-content/uploads/2021/05/Stage-1-Testicular-Cancer-Surveillance-Recommendations.pdf. Accessed May 24, 2023
Kollmannsberger C, Tandstad T, Bedard PL et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2014; 33: 51-57
Nayan M, Hamilton RJ. Dissecting the evolving risk of relapse over time in surveillance for testicular cancer. Adv Urol 2018; 2018: 7182014
Nayan M, Jewett MAS, Hosni A et al. Conditional risk of relapse in surveillance for clinical stage I testicular cancer. Eur Urol 2017; 71: 120-127
Dieckmann K-P, Simonsen-Richter H, Kulejewski M et al. Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment. Biomed Res Int 2019; 2019: 5030349
Hosni A, Warde P, Jewett M et al. Clinical characteristics and outcomes of late relapse in stage I testicular seminoma. Clin Oncol 2016; 28: 648-654
Chakiryan NH, Dahmen A, Cucchiara V et al. Reliability of serum tumor marker measurement to diagnose recurrence in patients with clinical stage I Nonseminomatous germ cell tumors undergoing active surveillance: a systematic review. J Urology 2021; 205: 1569-1576
Bandak M, Jørgensen N, Juul A et al. Testosterone deficiency in testicular cancer survivors - a systematic review and meta-analysis. Andrology-us 2016; 4: 382-388
Bandak M, Jørgensen N, Juul A et al. Longitudinal changes in serum levels of testosterone and luteinizing hormone in testicular cancer patients after orchiectomy alone or bleomycin, etoposide, and cisplatin. Eur Urol Focus 2018; 4: 591-598
Vignera SL, Cannarella R, Duca Y et al. Hypogonadism and sexual dysfunction in testicular tumor survivors: a systematic review. Front Endocrinol 2019; 10: 264
Sprauten M, Brydøy M, Haugnes HS et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol 2014; 32: 571-578
Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20: 4448-4452
Aparicio J, Germà JR, del Muro XG et al. Risk-adapted management for patients with clinical stage I seminoma: the second Spanish germ cell cancer cooperative group study. J Clin Oncol 2005; 23: 8717-8723
Mortensen MS, Lauritsen J, Gundgaard MG et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 2014; 66: 1172-1178
Pierorazio PM, Albers P, Black PC et al. Non-risk-adapted surveillance for stage I testicular cancer: critical review and summary. Eur Urol 2018; 73: 899-907
Blok JM, Pluim I, Daugaard G et al. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis. BJU Int 2020; 125: 355-368
Albers P, Siener R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German testicular cancer study group trial. J Clin Oncol Official J Am Soc Clin Oncol 2003; 21: 1505-1512
Pohar KS, Rabbani F, Bosl GJ et al. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol 2003; 170: 1155-1158
Tandstad T, Smaaland R, Solberg A et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian testicular cancer study group. J Clin Oncol 2011; 29: 719-725
Joffe JK, Cafferty FH, Murphy L et al. Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, noninferiority trial (TRISST). J Clin Oncol Official J Am Soc Clin Oncol 2022; 40: 2468-2478
Chung P, O'Malley ME, Jewett MAS et al. Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours. Eur Urol Oncol 2019; 2: 437-442
Tolan S, Vesprini D, Jewett MAS et al. No role for routine chest radiography in stage I seminoma surveillance. Eur Urol 2010; 57: 474-479
Mortensen MS, Lauritsen J, Kier MGG et al. Late relapses in stage I testicular cancer patients on surveillance. Eur Urol 2016; 70: 365-371
Tandstad T, Ståhl O, Håkansson U et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 2014; 25: 2167-2172
Cullen M, Huddart R, Joffe J et al. The 111 study: a single-arm, phase 3 trial evaluating one cycle of bleomycin, etoposide, and cisplatin as adjuvant chemotherapy in high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis. Eur Urol 2020; 77: 344-351
Travis LB, Fosså SD, Schonfeld SJ et al. Second cancers among 40 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97: 1354-1365
Shrem NS, Wood L, Hamilton RJ et al. Testicular cancer survivorship: long-term toxicity and management. Can Urol Assoc J 2022; 16: 257-272
De La Pena H, Sharma A, Glicksman C et al. No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer. Eur J Cancer 2017; 84: 354-359
Gietema JA, Meinardi MT, Sleijfer DT, Hoekstra HJ, van der Graaf WTA. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 2002; 13: 1616-1620
Daugaard G, Gundgaard MG, Mortensen MS et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 2014; 32: 3817-3823
Ackers C, Rustin GJS. Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours. Br J Cancer 2006; 94: 1231-1232
Fosså SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol Official J Am Soc Clin Oncol 2003; 21: 1249-1254